Cost-effectiveness of HMG coenzyme reductase inhibitors - Whom to treat?

Aims Treatment guidelines have been developed for both 'primary' and 'secon dary' prevention of coronary heart disease. These should consider both the efficacy as well as the costs of such treatment, particularly the costs of treatment with HMG co-enzyme A reductase inhibitors (statins). In the conte xt of guideline development in The Netherlands, the cost effectiveness of t reatment with statins was analysed. Methods Following a modelling approach, cost effectiveness was analysed as a function of a patient's initial risk for new coronary heart disease event s, combining results from 4S, CARE, LIPID, WOSCOPS and AFCAPS with Dutch co st data. For each sex and age group, an estimate was made of the level of c ardiovascular risks that might correspond to a cost-effectiveness ratio und er NLG 40 000 (Euro 18 151) per life year gained. Results If the 10-year risk of myocardial infarction, stroke or cardiovascu lar death was estimated at 9% (AFCAPS/ TexCAPS), 20% (WOSCOPS), 36%, (CARE) 36% (LIPID) and 47% (4S), cost effectiveness was estimated at Euro 51 400, Euro 26 013, Euro 9970, Euro 8028 and Euro 6695. The arbitrary threshold o f NLG 40 000 (approximately Euro 18 000) was achieved at a 10 year coronary heart disease event risk ranging from 19% to 26% for different age groups. Assuming the effectiveness of statin treatment decreased with age, a 10-ye ar risk, corresponding to Euro 18 000, varied from 11% (under age 30) to 41 % (over age 80). Patients at higher risk levels should be considered for st atin therapy. Conclusions Treatment costs for primary or secondary prevention are determi ned predominantly by the costs of statin drugs. The developed model allows comparison of cost effectiveness of statin therapy across a wide range of s ubjects with or without coronary heart disease. The consensus committee in the Netherlands postulated that drug therapy should be considered in subjec ts with or without coronary heart disease in which cost-effectivenesss is s imilar. Such groups can be identified using the presented model. When cost effectiveness ratios up to Euro 18 000 per life year gained are deemed acce ptable, statin treatment should be considered in most patients with known c ardiovascular disease (secondary prevention), and in a limited group of sub jects who are at high risk of developing coronary heart disease (primary pr evention). (Eur Heart J 2001; 22: 751-761, doi:10.1053/euhj.2000.2308) (C) 2001 The European Society of Cardiology.